Three-year follow-up analysis of automated microfoam preparation system for great saphenous vein incompetence and varicose veins sclerotherapy treatment
Restricted accessResearch articleFirst published online August, 2024
Three-year follow-up analysis of automated microfoam preparation system for great saphenous vein incompetence and varicose veins sclerotherapy treatment
To describe the treatment of patients with great saphenous vein (GSV) incompetence and varicose veins (VVs), utilizing an Automated Microfoam Preparation System (AMPS, Varixio®, VB Devices, Barcelona, Spain).
Methods
Adults between January and June 2021 were included. The AMPS system was used for foam preparation. Sclerotherapy treatment followed international recommendations. The primary endpoint was GSV closure rate after 36 months.
Results
164 patients were enrolled. During the 7-day follow-up period, all GSVs showed complete closure, which was maintained at the 1-year mark. No major complications were reported. A cumulative complete GSV recanalization rate of 6.1% and a partial recanalization rate of 26.8% after 36 months were noted. Some patients (9.7%) required additional treatment. A higher BMI was associated with complete recanalization.
Conclusion
The AMPS offers an easy-to-use and standardized procedure, potentially enhancing treatment outcomes if compared with manual preparation. Caution is advised when treating obese patients.
GianesiniSObiAOnidaS, et al.Global guidelines trends and controversies in lower limb venous and lymphatic disease: narrative literature revision and experts' opinions following the vWINter international meeting in Phlebology, Lymphology & Aesthetics, 23-25 January 2019. Phlebology2019; 34(1 Suppl): 4–66.
2.
DaviesHOPopplewellMDarvallK, et al.A review of randomised controlled trials comparing ultrasound-guided foam sclerotherapy with endothermal ablation for the treatment of great saphenous varicose veins. Phlebology2016; 31(4): 234–240.
3.
AlozaiTHuizingESchreveM, et al.A systematic review and meta-analysis of mechanochemical endovenous ablation using Flebogrif for varicose veins. J Vasc Surg Venous Lymphat Disord2022; 10(1): 248–257.e2.
4.
WitteMEZeebregtsCJde BorstGJ, et al.Mechanochemical endovenous ablation of saphenous veins using the ClariVein: a systematic review. Phlebology2017; 32(10): 649–657.
5.
SalernoMBissaccoDChiYW, et al.Empty vein ablation innovative technique for chronic venous disease treatment: proof of concept and ex-vivo analysis. Int Angiol2023; 42(5): 420–426.
6.
SalernoMBissaccoDChiYW, et al. Empty vein ablation (EVA) technique: an in-vivo animal model to assess the effects of sclerosing agent concentration and wall contact time on intima and media tunicae structure. Int Angiol. 2024. DOI:10.23736/S0392-9590.24.05147-2
7.
CavezziATessariL. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology2009; 24(6): 247–251.
8.
WongMParsiKMyersK, et al.Sclerotherapy of lower limb veins: indications, contraindications and treatment strategies to prevent complications - a consensus document of the International Union of Phlebology-2023. Phlebology2023; 38(4): 205–258.
9.
StarPConnorDEParsiK. Novel developments in foam sclerotherapy: focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins. Phlebology2018; 33(3): 150–162.
10.
RocheEPonsRRocheO, et al.A new automated system for the preparation of sclerosant foam: a study of the physical characteristics produced and the device settings required. Phlebology2020; 35(9): 724–733.
11.
von ElmEAltmanDGEggerM, et al.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology2007; 18: 800e4.
12.
PerrinMEklofBVAN RijA, et al.Venous symptoms: the SYM vein consensus statement developed under the auspices of the European venous forum. Int Angiol2016; 35(4): 374–398.
13.
De MaeseneerMGKakkosSKAherneT, et al.Editor's choice - European society for vascular surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg2022; 63(2): 184–267.
14.
RabeEBreuFXCavezziA, et al.Guideline Group. European guidelines for sclerotherapy in chronic venous disorders. Phlebology2014; 29(6): 338–354.
15.
BissaccoDStegherSCalliariFM, et al.Avoiding aesthetic complications after endovenous radiofrequency ablation. Phlebologie2017; 46(5): 278–280.
16.
PatelSBOstlerAEDos SantosSJ, et al.The effects of environmental and compositional manipulations on the longevity of Tessari-made foam for sclerotherapy. J Vasc Surg Venous Lymphat Disord2015; 3(3): 312–318.
17.
BaiTLiuYJiangW, et al.A review of sclerosing foam stability in the treatment of varicose veins. Dermatol Surg2020; 46(2): 249–257.
WatanabeSOkamuraAIwamotoM, et al.A randomized controlled trial to evaluate the safety and efficacy of transluminal injection of foam sclerotherapy compared with ultrasound-guided foam sclerotherapy during endovenous catheter ablation in patients with varicose veins. J Vasc Surg Venous Lymphat Disord2022; 10(1): 75–81.e1.
20.
UncuH. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Phlebology2010; 25(1): 44–49.
21.
BelcaroGCesaroneMRDi RenzoA, et al.Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). Angiology2003; 54(3): 307–315.
22.
NastasaVSamarasKAmpatzidisC, et al.Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm2015; 478(2): 588–596.
23.
RobertsTGCoxSJLewisAL, et al.Characterisation and optimisation of foams for varicose vein sclerotherapy. Biorheology2020; 57(2-4): 77–85.
24.
LomazziCBissaccoDLoganMS, et al.Risk factors for saphenous vein recanalization after endovenous radiofrequency ablation. J Cardiovasc Surg2021; 62(5): 427–434.
